In a patient with known myelodysplastic syndrome who has experienced recurrent infections for two months, what are the possible differential diagnoses?

Differential Diagnoses for PUO in MDS with Recurrent Infections

In an MDS patient with 2 months of recurrent infections and pyrexia of unknown origin, the primary differentials are bacterial infections (particularly pneumonia and skin/soft tissue infections), followed by fungal infections in neutropenic patients, disease progression to higher-risk MDS or AML transformation, and less commonly viral infections or drug-related fever.

Infection-Related Differentials (Most Common)

Bacterial Infections

Bacterial infections account for the majority of infectious complications in MDS patients 1, 2, 3. The specific patterns include:

• Pneumonia - Most common bacterial infection in MDS 3
• Skin and soft tissue abscesses - Second most common 3
• Sinopulmonary infections - Particularly if hypogammaglobulinemia present 4
• Septicemia from encapsulated organisms (S. pneumoniae, H. influenzae) 4
• Catheter-related bloodstream infections - If central venous access present

The infection rate in MDS is approximately one per patient-year, with rates varying by MDS subtype: RA/RARS < RAEB < RAEB-T 3. Infection is the leading cause of death in MDS, accounting for 64% of mortality 3, making this the most critical differential to evaluate.

Fungal Infections

Consider invasive fungal infections, particularly if:

• Absolute neutrophil count <500/μL 1
• Unfavorable cytogenetics present 1
• Prior intensive chemotherapy or hypomethylating agent therapy 1, 2
• Thrombocytopenia present 1

The incidence of fungal infections in MDS is not well-established but increases significantly with neutropenia severity 2.

Viral Infections

Less common but include 5, 4:

• CMV reactivation (check CMV status per guidelines) 6
• HSV/VZV reactivation
• Parvovirus B19 (particularly in hypoplastic MDS) 5
• Hepatitis B/C (especially in transfusion-dependent patients) 5

Disease-Related Differentials

MDS Progression/Transformation

Evaluate for evolution to higher-risk MDS or AML transformation 6:

• Increasing blast percentage (repeat bone marrow examination may be needed) 5
• Worsening cytopenias
• New cytogenetic abnormalities
• Development of constitutional symptoms

The clinical history should document "timing, severity, and tempo of abnormal cytopenias; prior infections or bleeding episodes" 6 to distinguish stable MDS from evolving disease.

Bone Marrow Failure Complications

• Progressive neutropenia with functional neutrophil defects 2, 7
• Immune dysregulation (B-cell, T-cell, NK-cell defects) 2

Other Differentials to Exclude

Drug-Related Fever

If receiving MDS-directed therapy:

• Hypomethylating agents (azacitidine, decitabine) - can transiently worsen neutropenia 2
• Lenalidomide 2
• G-CSF (if used) 8

Iron Overload Complications

In transfusion-dependent patients, check serum ferritin 6 - iron overload may contribute to immune dysfunction 2.

Autoimmune/Inflammatory Conditions

Exclude concurrent autoimmune disorders 5 as MDS can coexist with immune dysregulation.

Critical Diagnostic Workup

Mandatory immediate investigations 5:

• Complete blood count with differential
• Blood cultures (bacterial and fungal)
• Chest imaging for pneumonia
• Urinalysis and urine culture
• Skin examination for abscesses
• Inflammatory markers (CRP, ESR)

Essential MDS-specific workup 6, 5:

• Repeat bone marrow aspirate and biopsy if disease progression suspected
• Cytogenetics (critical for prognosis) 6
• Serum ferritin
• CMV PCR if clinically indicated 6
• HIV screening if risk factors present 5

Consider based on clinical context 5:

• PNH screening (flow cytometry)
• Fungal biomarkers (galactomannan, beta-D-glucan) if neutropenic
• Viral serologies (hepatitis B/C, parvovirus B19)

Key Risk Factors to Assess

The infection risk stratifies by 1, 3:

• Neutrophil count: <500/μL = highest risk, <1000/μL = elevated risk
• MDS subtype: RAEB-T > RAEB > RA/RARS
• Cytogenetics: Unfavorable cytogenetics increase infection risk 1
• Thrombocytopenia: Independent risk factor 1
• Prior therapy: Multiple chemotherapy lines increase risk 4

Common Pitfalls

• Do not assume fever is always infectious - consider disease progression requiring repeat marrow examination 5
• Neutrophil count alone is insufficient - functional neutrophil defects occur even with normal counts 2, 7
• Aggressive evaluation is mandatory - infection is the leading cause of death, not leukemic transformation 3
• Consider atypical organisms - immunocompromised state predisposes to opportunistic pathogens 4